Navigation Links
Tamoxifen Helps Treat Bipolar Disorder
Date:9/12/2007

Discovery may lead to new drug to treat manic phase of the illness, study says

WEDNESDAY, Sept. 12 (HealthDay News) -- The breast cancer drug tamoxifen helps control the manic phase of bipolar disorder, and works faster than many standard medications used to treat the chronic mental illness, a new study has found.

"One of the problems with existing treatments for bipolar disorder is they seem to have this long period before they start to work," explained Dr. Husseini K. Manji, senior study author and director of the U.S. National Institute of Mental Health's mood and anxiety disorders program.

Current treatments sometimes take weeks to become effective, Manji said. "And that obviously creates a huge problem," he said. When patients are in the manic phase, particularly, not getting relief fast enough from medication may mean they need to be hospitalized, he noted.

For the study, Manji and his colleagues gave eight patients experiencing a manic episode tamoxifen, while another eight received a placebo; no one knew which drug they were getting. After three weeks, 63 percent of those on tamoxifen had reduced symptoms of mania, compared to just 13 percent of those on a placebo. The tamoxifen group responded by the fifth day of treatment.

The study results are published online in the September issue of Bipolar Disorders.

Manji and his colleagues decided to study tamoxifen because they knew that standard medications used to treat mania are known to lower the activity of an enzyme called protein kinase C, or PKC, that regulates activities in brain cells. This enzyme is believed to become overactive when bipolar disorder patients experience a manic episode.

Tamoxifen also blocks PKC, but does it more directly than some bipolar drugs, according to the researchers.

Manji and his team made the discovery after years of searching for the correct cellular target to treat bipolar disorder, which affects almost 6 million American adults. Symptoms can be disabling, including profound mood swings, from depression to the manic phase, during which people can become overly excited and energetic but also irritable, before they plunge into depression again.

For the study, Manji said, "we started with 20 milligrams [of tamoxifen] a day. It was increased each day, usually up to 100 milligrams a day. "Literally at day five we saw this significant anti-mania effect," he said, adding that with standard medications it would have taken three weeks to see results.

"If we had something that would nip mania in the bud, it might save people from being hospitalized and getting sedating agents," Manji said.

A new bipolar drug would not be tamoxifen itself, he said, but rather another medicine that mimics what tamoxifen does in the brain. The development of such a drug would probably take at least five years before it could be approved for marketing, he said.

Dr. Gary S. Sachs, director of the bipolar clinic and research program at Massachusetts General Hospital and associate professor of psychiatry at Harvard Medical School, called the results "encouraging."

Sachs said he was aware of other research with similar findings. "I wouldn't say this study proves that tamoxifen works faster than standard [treatment,]" he said, since a head-to-head comparison was not done. But, while not definitive, "the study has important findings," he said.

More information

To learn more about bipolar disorder, visit the U.S. National Institute of Mental Health.



SOURCES: Husseini K. Manji, M.D., director, mood and anxiety disorders program, National Institute of Mental Health, Bethesda, Md.; Gary Sachs, M.D., director, bipolar clinic and research program, Massachusetts General Hospital, and associate professor, psychiatry, Harvard Medical School, Boston; September 2007 Bipolar Disorders, online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Letrozole Beats Tamoxifen in Breast Cancer Therapy
2. Tamoxifen does not adversely affect the brain
3. Tamoxifen reduces breast cancer risk
4. Tamoxifen reduces breast cancer risk
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
7. New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse
8. Raloxifene Better Than Tamoxifen For Breast Cancer
9. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
10. Study Identifies Mechanism Which May Help Tamoxifen Work Better
11. Tamoxifen Discontinuation Rates Surprisingly High
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the ... Group of New York was founded by James M. Maisel, MD and has been providing ... Shah has always followed a legacy of surpassing expectations amongst her peers. Growing up ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic ... Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care ... Dallas area” Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards ... School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors ...
(Date:12/4/2016)... ... 04, 2016 , ... Responsible dental care hinges on regular brushing of the ... results. This important necessity inspired an inventor from Las Vegas, Nev., to design the ... people break or avoid bad techniques of brushing the teeth in order to prevent ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
Breaking Medicine Technology: